Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group.
Per Pfeiffer
No relevant relationships to disclose
Halfdan Sorbye
Research Funding - Amgen; Merck; Roche
Camilla Qvortrup
No relevant relationships to disclose
Mia Karlberg
No relevant relationships to disclose
Gisela Naucler
No relevant relationships to disclose
Christian Kersten
No relevant relationships to disclose
Kirsten Vistisen
No relevant relationships to disclose
Birgitta Lindh
No relevant relationships to disclose
Bengt Glimelius
No relevant relationships to disclose